Tyra Biosciences, Inc.(TYRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TYRA Tyra Biosciences, Inc.

Closed 12-18 16:00:00 EST

22.99

+0.39

+1.73%

盘后22.99

+0.000.00%

17:40 EST

High23.39	Low22.63	Vol414.41K
Open22.71	D1 Closing22.60	Amplitude3.36%
Mkt Cap1.23B	Tradable Cap395.87M	Total Shares53.37M
T/O9.51M	T/O Rate2.41%	Tradable Shares17.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TYRA","market":"US","secType":"STK","nameCN":"Tyra Biosciences, Inc.","latestPrice":22.99,"timestamp":1766091600000,"preClose":22.6,"halted":0,"volume":414407,"hourTrading":{"tag":"盘后","latestPrice":22.99,"preClose":22.99,"latestTime":"17:40 EST","volume":8843,"amount":203299.73,"timestamp":1766097655428},"delay":0,"floatShares":17219026,"shares":53372098,"eps":-1.879839,"marketStatus":"Closed","change":0.39,"latestTime":"12-18 16:00:00 EST","open":22.71,"high":23.39,"low":22.63,"amount":9512337.232258001,"amplitude":0.033628,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.879839,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1631678400000,"exchange":"NASDAQ","adjPreClose":22.6,"preHourTrading":{"tag":"盘前","latestPrice":22.6,"preClose":22.6,"latestTime":"08:38 EST","volume":3087,"amount":69582.520413,"timestamp":1766065125384},"postHourTrading":{"tag":"盘后","latestPrice":22.99,"preClose":22.99,"latestTime":"17:40 EST","volume":8843,"amount":203299.73,"timestamp":1766097655428},"volumeRatio":1.054527,"impliedVol":0.1259,"impliedVolPercentile":0.064},"requestUrl":"/m/hq/s/TYRA/tweets","defaultTab":"tweets","newsList":[{"id":"2592305829","title":"Tyra Biosciences Chief Discovery Officer Daniel Bensen Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592305829","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592305829?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:30","pubTimestamp":1765920655,"startTime":"0","endTime":"0","summary":"Daniel Bensen, Chief Discovery Officer of Tyra Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL32B0lf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tyra Biosciences Chief Discovery Officer Daniel Bensen Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TYRA"],"gpt_icon":0},{"id":"2591528984","title":"Tyra Biosciences Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2591528984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591528984?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:46","pubTimestamp":1765889160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TYRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 07:46 ET (12:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA"],"gpt_icon":0},{"id":"2591981932","title":"Wedbush Raises Price Target on Tyra Bioscience to $37 From $30, Adds Stock to Best Ideas List, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981932","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981932?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:20","pubTimestamp":1765887638,"startTime":"0","endTime":"0","summary":"Tyra Bioscience (TYRA) has an average rating of buy and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2591813719","title":"Tyra Biosciences Inc : Wedbush Raises Target Price to $37 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2591813719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591813719?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:16","pubTimestamp":1765887419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2591510644","title":"Assessing Tyra Biosciences (TYRA) Valuation Following Key Executive Hires to Support Advancing Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2591510644","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591510644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:16","pubTimestamp":1765800998,"startTime":"0","endTime":"0","summary":"Tyra Biosciences (TYRA) just reshuffled its leadership bench, bringing in regulatory veteran Heather Faulds as Chief Regulatory Officer and commercial operator Bhavesh Ashar as Chief Operating Officer to help steer its advancing clinical pipeline.\nSee our latest analysis for Tyra Biosciences.\nThose hires land as Tyra’s share price has climbed to $22.63, with a 30 day share price return of 43.87 percent and a three year total shareholder return of 222.36 percent, which signals strong and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-following-key-exec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-following-key-exec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TYRA"],"gpt_icon":0},{"id":"2590585305","title":"How Investors Are Reacting To Tyra Biosciences (TYRA) Bolstering Its Regulatory And Oncology Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2590585305","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590585305?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:23","pubTimestamp":1765344193,"startTime":"0","endTime":"0","summary":"Tyra Biosciences recently strengthened its leadership team by appointing Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, both bringing extensive oncology and regulatory experience from major biopharma companies.\nTheir track records in securing approvals for complex medicines and launching rare oncology products could be particularly important as Tyra advances oral dabogratinib through global Phase 2 studies.\nWith these leadership changes in place,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/how-investors-are-reacting-to-tyra-biosciences-tyra-bolsteri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/how-investors-are-reacting-to-tyra-biosciences-tyra-bolsteri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4139","TYRA","ISBC"],"gpt_icon":0},{"id":"2588546070","title":"Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires to Drive Dabogratinib Pipeline Forward","url":"https://stock-news.laohu8.com/highlight/detail?id=2588546070","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588546070?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:29","pubTimestamp":1764815352,"startTime":"0","endTime":"0","summary":"Tyra Biosciences (TYRA) is shaking up its leadership team, bringing in seasoned operators Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, with a clear focus on advancing oral dabogratinib.\nSee our latest analysis for Tyra Biosciences.\nThe leadership shake up lands at a time when sentiment is already improving, with a roughly 45 percent 1 month share price return helping drive a stronger 3 month share price performance and underlining building momentum...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/tyra-biosciences-tyra-assessing-valuation-after-new-leadersh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/tyra-biosciences-tyra-assessing-valuation-after-new-leadersh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TYRA"],"gpt_icon":0},{"id":"2588304709","title":"Tyra Biosciences Inc. Files Initial Statement of Beneficial Ownership for COO Bhavesh Ashar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304709","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304709?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:16","pubTimestamp":1764631015,"startTime":"0","endTime":"0","summary":"Tyra Biosciences Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Bhavesh Ashar as the beneficial owner in his role as Chief Operating Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL15mtsx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TYRA"],"gpt_icon":0},{"id":"2588720877","title":"BRIEF-Tyra Biosciences Strengthens Leadership Team With Appointments Of Bhavesh Ashar As Chief Operating Officer And Heather Faulds As Chief Regulatory Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720877","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720877?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594044,"startTime":"0","endTime":"0","summary":"BRIEF-Tyra Biosciences Strengthens Leadership Team With Appointments Of Bhavesh Ashar As Chief Operating Officer And Heather Faulds As Chief Regulatory OfficerDec 1 (Reuters) - Tyra Biosciences Inc TY","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUABSTZ5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2588720831","title":"Tyra Biosciences Strengthens Leadership Team With Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720831","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720831?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUABSTZ5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2586043514","title":"Tyra Biosciences Director Robert J. More Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586043514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586043514?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:07","pubTimestamp":1764108478,"startTime":"0","endTime":"0","summary":"Robert J. More, Director of Tyra Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1WRJn2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tyra Biosciences Director Robert J. More Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2584927014","title":"Tyra Bioscience Currently Up Nine Consecutive Days, On Track for Record Winning Streak -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2584927014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584927014?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:04","pubTimestamp":1763575440,"startTime":"0","endTime":"0","summary":"Tyra Bioscience, Inc  is currently at $16.13, up $0.09 or 0.56%. --Would be highest close since Jan. 23, 2025, when it closed at $16.24. --Currently up nine consecutive days; up 12.96% over this period. --Up 16.04% year-to-date; on pace for best year since 2023, when it rose 82.24%. --Down 48.55% from its all-time closing high of $31.35 on Nov. 4, 2021. --Up 1.64% from 52 weeks ago , when it closed at $15.87. --Down 3.59% from its 52-week closing high of $16.73 on Jan. 15, 2025. --Up 128.47% from its 52-week closing low of $7.06 on April 8, 2025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2584893162","title":"Bank of America Securities Sticks to Its Buy Rating for Tyra Bioscience (TYRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893162?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:38","pubTimestamp":1763465896,"startTime":"0","endTime":"0","summary":"In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Tyra Bioscience, with a price target of $28.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-tyra-bioscience-tyra-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-tyra-bioscience-tyra-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TYRA","BAC"],"gpt_icon":0},{"id":"2584360384","title":"Tyra Biosciences COO Daniel Bensen Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584360384","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584360384?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:04","pubTimestamp":1763424272,"startTime":"0","endTime":"0","summary":"Daniel Bensen, Chief Operating Officer of Tyra Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL32FbDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tyra Biosciences COO Daniel Bensen Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"1153231346","title":"Stock Track | Tyra Biosciences Plummets 9.92% Pre-Market Following Q3 Earnings Report Showing Increased Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1153231346","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153231346?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:46","pubTimestamp":1762440415,"startTime":"0","endTime":"0","summary":"Shares of Tyra Biosciences, Inc. (TYRA) plunged 9.92% in pre-market trading on Thursday, following the release of the company's third-quarter earnings report. The biotechnology firm, which focuses on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TYRA"],"gpt_icon":0},{"id":"2581310180","title":"Tyra Biosciences Reports Increased Loss Amid R&D Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581310180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581310180?lang=en_us&edition=fundamental","pubTime":"2025-11-06 13:14","pubTimestamp":1762406090,"startTime":"0","endTime":"0","summary":"Tyra Bioscience, Inc ( ($TYRA) ) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyra-biosciences-reports-increased-loss-amid-rd-investments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyra-biosciences-reports-increased-loss-amid-rd-investments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2581394370","title":"Tyra Bioscience (TYRA) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581394370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581394370?lang=en_us&edition=fundamental","pubTime":"2025-11-06 12:36","pubTimestamp":1762403761,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Tyra Bioscience yesterday and set a price target of $36.00. According to TipRanks, B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tyra-bioscience-tyra-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tyra-bioscience-tyra-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TYRA","BK4127","BK4139","OPY"],"gpt_icon":0},{"id":"2581700581","title":"Tyra Biosciences Q3 EPS $(0.50), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2581700581","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581700581?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:48","pubTimestamp":1762379339,"startTime":"0","endTime":"0","summary":"Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.50) per share which met the analyst consensus estimate. This is a 21.95 percent decrease over losses of $(0.41) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48671439/tyra-biosciences-q3-eps-0-50-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tyra Biosciences Q3 EPS $(0.50), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA"],"gpt_icon":0},{"id":"2581370164","title":"Tyra Biosciences posts Q3 results with $274.9 million in cash and equivalents","url":"https://stock-news.laohu8.com/highlight/detail?id=2581370164","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581370164?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:06","pubTimestamp":1762376777,"startTime":"0","endTime":"0","summary":"Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1N4kl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYRA","BK4139"],"gpt_icon":0},{"id":"2581707148","title":"Tyra Biosciences: Cash, Cash Equivalents, and Marketable Securities of $274.9 Mln at Q3 2025; Runway Through at Least 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581707148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581707148?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:05","pubTimestamp":1762376701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXA99680:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TYRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tyra.bio","stockEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.4214},{"period":"3month","weight":0.767},{"period":"6month","weight":1.4485},{"period":"1year","weight":0.4849},{"period":"ytd","weight":0.6259}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.084234},{"month":2,"riseRate":0.5,"avgChangeRate":0.112345},{"month":3,"riseRate":0.25,"avgChangeRate":-0.066485},{"month":4,"riseRate":0.5,"avgChangeRate":-0.067473},{"month":5,"riseRate":0.25,"avgChangeRate":-0.058118},{"month":6,"riseRate":0.75,"avgChangeRate":0.065309},{"month":7,"riseRate":0.75,"avgChangeRate":0.221929},{"month":8,"riseRate":0.75,"avgChangeRate":-0.041352},{"month":9,"riseRate":0.75,"avgChangeRate":0.092769},{"month":10,"riseRate":0.4,"avgChangeRate":-0.051145},{"month":11,"riseRate":0.8,"avgChangeRate":0.101474},{"month":12,"riseRate":0.6,"avgChangeRate":-0.05681}],"exchange":"NASDAQ","name":"Tyra Biosciences, Inc.","nameEN":"Tyra Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tyra Biosciences, Inc.(TYRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tyra Biosciences, Inc.(TYRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tyra Biosciences, Inc.,TYRA,Tyra Biosciences, Inc.股票,Tyra Biosciences, Inc.股票老虎,Tyra Biosciences, Inc.股票老虎国际,Tyra Biosciences, Inc.行情,Tyra Biosciences, Inc.股票行情,Tyra Biosciences, Inc.股价,Tyra Biosciences, Inc.股市,Tyra Biosciences, Inc.股票价格,Tyra Biosciences, Inc.股票交易,Tyra Biosciences, Inc.股票购买,Tyra Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tyra Biosciences, Inc.(TYRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tyra Biosciences, Inc.(TYRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction